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Abstract
Objective: To investigate the association between total serum cholesterol (TSC) and cancer incidence in the Metabolic
syndrome and Cancer project (Me-Can).
Methods: Me-Can consists of seven cohorts from Norway, Austria, and Sweden including 289,273 male and 288,057 female
participants prospectively followed up for cancer incidence (n = 38,978) with a mean follow-up of 11.7 years. Cox regression
models with age as the underlying time metric were used to estimate hazard ratios (HR) and their 95% confidence intervals
(CI) for quintiles of cholesterol levels and per 1 mmol/l, adjusting for age at first measurement, body mass index (BMI), and
smoking status. Estimates were corrected for regression dilution bias. Furthermore, we performed lag time analyses,
excluding different times of follow-up, in order to check for reverse causation.
Results: In men, compared with the 1st quintile, TSC concentrations in the 5th quintile were borderline significantly
associated with decreasing risk of total cancer (HR = 0.94; 95%CI: 0.88, 1.00). Significant inverse associations were observed
for cancers of the liver/intrahepatic bile duct (HR = 0.14; 95%CI: 0.07, 0.29), pancreas cancer (HR = 0.52, 95% CI: 0.33, 0.81),
non-melanoma of skin (HR = 0.67; 95%CI: 0.46, 0.95), and cancers of the lymph2/hematopoietic tissue (HR = 0.68, 95%CI:
0.54, 0.87). In women, hazard ratios for the 5th quintile were associated with decreasing risk of total cancer (HR = 0.86,
95%CI: 0.79, 0.93) and for cancers of the gallbladder (HR = 0.23, 95%CI: 0.08, 0.62), breast (HR = 0.70, 95%CI: 0.61, 0.81),
melanoma of skin (HR = 0.61, 95%CI: 0.42, 0.88), and cancers of the lymph2/hematopoietic tissue (HR = 0.61, 95%CI: 0.44,
0.83).
Conclusion: TSC was negatively associated with risk of cancer overall in females and risk of cancer at several sites in both
males and females. In lag time analyses some associations persisted, suggesting that for these cancer sites reverse causation
did not apply.
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Introduction
Since the 1980s several epidemiological studies have reported
an association between higher total serum cholesterol (TSC) levels
and lower overall or site-specific cancer incidence and mortality
[1–9], whereas others found higher cancer risk in people with high
TSC levels [10–13], no significant relation [14–18], or a U-shaped
association, that is both low and high TSC levels being
significantly associated with increased cancer risk [19].
It has been suggested that the observed inverse associations have
to be attributed to an effect of preclinical cancer or disease on
cholesterol levels (i.e. metabolic depression or increased utilization
of cholesterol during carcinogenesis [20]) rather than reflecting
a true causal relationship. The hypothesis of reverse causation is
strongly supported by a recent Mendelian randomization study
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[21] and by the observation that the inverse associations between
high cholesterol levels and cancer risk and mortality weakened or
even disappeared when the first few years of study follow-up were
excluded [1,9,22]. However, some studies found inverse associa-
tions with time lags of 4 or even more years between baseline
cholesterol level and cancer diagnosis [7,20,23], so the possibility
that there may be a direct effect of low cholesterol on cancer can
still not be completely ruled out.
More recent studies [24,25] on cholesterol and cancer in-
cidence, including partly data also used in this study [25], added
additional evidence for the reverse causation hypothesis again.
Nevertheless, relatively modest sample sizes and differences in
study populations, length of follow-up, study endpoints and
statistical procedures may all have contributed to the lack of
consistency in results of previous studies.
Assessment of cholesterol levels on a single occasion results in
a substantial random error due to variability in the measurement
process or real but short-term biological variability. Such
inaccuracy in exposure measurement may lead to underestimation
[26] of the risk factor outcome association through the so called
regression dilution bias. Prospective studies on metabolic factors
and risk of cardiovascular disease, which utilized repeated
exposure measurement to apply methods to correct for regression
dilution bias, presented stronger associations than those based on
single baseline measured exposures [27–29].
Motivated by the inconsistency in the literature and the failure
to account for regression dilution, the aim of this study was to
investigate the association between TSC and the overall and site-
specific cancer incidence in a large study population containing
seven European cohorts.
Materials and Methods
Study Population
The Metabolic syndrome and Cancer project (Me-Can)
includes data from population-based cohorts from Norway,
Austria, and Sweden, and aims at investigating associations
between metabolic factors and cancer risk.
A detailed description of the project has been published
previously [30]. In 2006, data from seven existing cohorts from
Norway (Oslo study, Norwegian Counties study, the Cohort of
Norway, Age 40 programme), Austria (Vorarlberg Health
Monitoring and Prevention Programme), and Sweden (Va¨ster-
botten Intervention Project, Malmo¨ Preventive Project) were
pooled. Participants in the cohorts had undergone one or more
health examinations between 1972 and 2005, and information on
lifestyle and socio-demographic factors had been recorded and
available data have been managed accordingly. For the present
study information on age, weight, height, TSC level, and smoking
status of 289,273 men and 288,057 women was used.
Measurements
Anthropometric measurements were conducted in a similar way
in all Me-Can cohorts, with participants wearing light indoor
clothes and no shoes. Regarding smoking habits, participants were
asked to fill in a questionnaire except in VHM&PP where
respective questions were asked by the examining physician and
the information was entered directly into a database. Participants
were classified as never, former, and current smokers.
Fasting time before blood was drawn varied across the different
cohorts [30]. In the Norwegian cohorts, fasting was not required
before the examination, and fasting time was recorded as less than
1, 1–2, 2–4, 4–8, or more than 8 hours. Fasting time in
Va¨sterbotten Intervention Project was recorded as less than 4,
4–8, or more than 8 hours, and from 1992 onwards, participants
were asked to fast for at least 8 hours before the examination. In
Malmo¨ Preventive Project and, after the initial 3 years, in the
Austrian programme, a minimum of 8 hours of fasting was used as
the standard procedure. For the analyses, information on fasting
status was summarized into the categories of less than 4, 4–8, and
more than 8 hours.
In the Oslo and the Norwegian Counties study serum levels of
total cholesterol were measured applying a non-enzymatic
method, whereas in all other cohorts an enzymatic method was
used. Measurements obtained by a non-enzymatic method have
been transformed according to 0.926(cholesterol level) - 0.03 and
are presented in mmol/l [30].
Identification of Cases and Cohort Follow-up
Incident cancer cases were identified through linkages with
national cancer registries of the respective countries and catego-
rized according to the International Classification of Diseases,
seventh revision. Follow-up ended at the date of the first primary
cancer diagnosis, emigration, death or December 31, 2003 (in
Austria), 2005 (in Norway), or 2006 (in Sweden), whichever
occurred first.
Statistical Analysis
Cox proportional hazard regression analyses were applied for
men and women separately to investigate the association between
TSC levels and site-specific cancer incidence. Subjects were
followed until the date of first cancer diagnosis or were censored as
described above. When analyzing a specific cancer site, this site
was regarded as an event whereas all other sites were censored.
Hazard ratios (HR) and respective 95% confidence intervals (CI)
were estimated for TSC levels in quintiles (with cut-off levels
determined separately for each sex, cohort, and fasting time
category) and as a continuous variable (HRs per 1 mmol/l
increment).
Age was utilized as the underlying time metric and all estimates
were stratified by cohort, fasting time, and categories of birth year
(before 1929, 1930–1939, 1940–1949, 1950–1959, 1960–1969,
1970 and later). Additionally, all analyses included adjustment for
age at baseline (continuous), body mass index (BMI categories
,22.5, 22.5–,25.0, 25.0–,27.5, 27.5–,30.0, 30.0–,32.5,
$32.5- kg/m2), and smoking status (categories never, former,
current smoker). Linear tests for trend were performed including
TSC quintiles as an ordinal variable.
The proportionality assumption was checked applying a test
based on Schoenfeld residuals. For some cancer sites there was an
indication of violation of the proportionality assumption for BMI
or smoking status. Additional models stratified for the respective
variable were fitted, however estimates of hazard ratios for TSC
did not change markedly. To check for reverse causation, various
lag-time analyses were carried out, leaving out the first year, the
first 5 years, and the first 10 years of follow-up.
In the main analyses hazard ratios were corrected for random
error in TSC measurements using a method involving calculation
of regression dilution ratio (RDR), similar to that described by
Wood et al. [31]. Additionally, uncorrected hazard ratios were
calculated and presented in supplement tables. Calculation of
RDRs was based on data from subjects for whom two or more
observations with the same fasting time before measurement were
available; in total, data from 133,820 subjects and 406,364 health
examinations were available. Altogether, the mean time between
the baseline and the repeated measurement was 6.9 years
(standard deviation [SD] = 3.9). Linear mixed effects models,
treating the repeated measurements as the dependent variable and
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the baseline measurements as the independent variable and
further including age at baseline, fasting time, smoking status, sex,
birth year, BMI, and time since date of baseline examination as
fixed effects and cohort as a random effect, were fitted. RDRs were
estimated as the predicted regression coefficient at the time point
six years after baseline measurement, i.e. at half the follow-up
time. The obtained RDRs for TSC were 0.644 in men and 0.660
in women. Correction of hazard ratios was achieved by calculating
exp (ln (HR)/RDR).
To assess whether statin prescription had an effect on the
association between TSC and cancer incidence, additional
analyses were performed with only baseline measurements that
had been obtained before 1994. This timepoint was selected as the
Scandinavian Simvastatin Study published in 1994 [32] was
regarded as the starting point for the afterwards steadily increasing
statin prescription.
Statistical analyses were performed with Stata (version 10,
StataCorp LP, College Station, Texas) and R (version 2.7.2, used
for RDR calculation). Two-sided P values lower than 0.05 were
considered statistically significant.
Ethics
The study was approved by The Research Review Board of
Umea˚, Sweden, the Regional Committee for Medical and Health
Research Ethics, Southeast Norway and the Ethikommission of
the Land Vorarlberg, Austria. Participants from Sweden and
Austria provided written informed consent to participate in this
study. In Norway, the participants were invited to come to the
health survey and a questionnaire was sent together with the
invitation. An attendance to the health examination where the
participants delivered their filled in questionnaire, has been
accepted by the Data Inspectorate as an informed consent, but
not a written consent. Written consent was obtained from 1994.
Results
Baseline Characteristics
In Table 1 baseline characteristics of the study population are
presented by cohort. Mean age at baseline varied between 40.3
(SD = 7.0) years in the NCS cohort and 47.5 (15.0) years in
CONOR. BMI was highest in the Oslo cohort 26.6 (2.9) and
lowest in NCS and MPP. The highest rate of people suffering from
hypercholesterolaemia (TSC.6.2 mmol/l) was observed in the
Oslo cohort with 50.2%, the lowest in the 40-y cohort with 23.4%.
Mean follow-up ranged from 26.0 (8.0) years in the Oslo cohort to
6.1 (2.4) years in CONOR.
TSC and Risk of Incident Cancer
Hazard ratios corrected for regression dilution bias for total and
site-specific cancer incidence by quintiles and per unit increment
of TSC are presented in Table 2 and Table 3 for men and women
respectively. In addition, uncorrected estimates can be found in
Tables S1 and Tables S2.
Among men, compared with the first quintile, TSC concentra-
tions in the fifth quintile were borderline significantly associated
with decreasing risk of total cancer (HR = 0.94; 95%CI: 0.88,
1.00) and significant inverse associations were observed for cancers
of the liver/intrahepatic bile duct (HR = 0.14; 95%CI: 0.07, 0.29),
pancreas cancer (HR = 0.52, 95% CI: 0.33, 0.81), non-melanoma
of skin (HR = 0.67; 95%CI: 0.46, 0.95), and cancers of the lymph/
hematopoietic tissue (HR = 0.68, 95%CI: 0.54, 0.87). Similar
associations were observed when one unit increments of TSC were
considered (Table 2).
In women, the hazard ratio for the fifth quintile was associated
with decreasing risk of total cancer (HR = 0.86, 95%CI: 0.79,
0.93) and furthermore for cancers of the gallbladder (HR = 0.23,
95%CI: 0.08, 0.62), breast (HR = 0.70, 95%CI: 0.61, 0.81),
melanoma of skin (HR = 0.61, 95%CI: 0.42, 0.88) and cancers of
the lymph2/hematopoietic tissue (HR = 0.61, 95%CI: 0.44, 0.83).
Hazard ratios per one unit TSC increment showed similar inverse
associations. Additionally, a borderline significant association was
observed for cancers of other parts of uterus (HR = 0.91, 95%CI:
0.84, 0.99).
Lag-time Analysis
Considering males, comparing the fifth to the first quintile in
lag-time analyses, after leaving out the first year of follow-up
significant inverse associations persisted for cancers of the liver/
intrahepatic bile ducts (HR = 0.15, 95%CI: 0.08, 0.31) and
pancreas cancer (HR = 0.54, 95%CI: 0.35, 0.85). Furthermore,
a borderline positive association for colon cancer (HR = 1.30,
95%CI: 1.01, 1.68) was observed. Leaving out the first five years of
follow-up, significant inverse associations were still observed for
cancers of the liver/intrahepatic bile ducts (HR = 0.24, 95%CI:
0.11, 0.53), pancreas (HR = 0.48, 95%CI: 0.30, 0.78) and non-
melanoma of skin (HR = 0.63, 95%CI: 0.42, 0.94). There was
again a positive association of TSC with colon cancer (HR = 1.46,
95%CI: 1.10, 1.92). When the first ten years of follow-up were
excluded, only associations with pancreas cancer (HR = 0.50,
95%CI: 0.29, 0.88) non-melanoma of skin (HR = 0.56, 95%CI:
0.36, 0.89) and colon cancer (HR = 1.44, 95%CI: 1.05, 1.98)
remained.
In females, all reported associations comparing the fifth to the
first quintile persisted, when the first year of follow-up was
excluded (total cancer HR = 0.90, 95%CI: 0.83, 0.98; gallbladder
HR = 0.25, 95%CI: 0.09, 0.71; breast HR = 0.72, 95%CI: 0.62,
0.83; melanoma of skin HR = 0.60, 95%CI: 0.41, 0.89; cancers of
the lymph/hematopoietic tissue HR = 0.65, 95%CI: 0.47, 0.90).
When the first 5 years were left out, significant associations with
breast cancer (HR = 0.71, 95%CI: 0.60, 0.85) and melanoma of
skin (HR = 0.54, 95%CI: 0.33, 0.87) were still observed, which
also persisted when the first ten years of follow-up were excluded
(breast cancer HR = 0.62, 95%CI: 0.49, 0.80; melanoma of skin
HR = 0.46, 95%CI: 0.21, 0.96).
Sub-analyses before 1994, the Onset of Statin Medication
Results of the sub-analyses including cholesterol data before
1994 are presented in Tables S3 and S4. The results did not show
substantial differences in comparison to the main analyses with
some exceptions, e.g. the inverse association of TSC with cancer
became insignificant for pancreas cancer and cancers of the
lymph2/hematopoietic tissue.
Discussion
In the present prospective cohort study, elevated TSC levels
were significantly associated with decreased risk of cancer
incidence in general and with several site-specific cancers in men
and women. With the exception of male colon cancer we only
found no or inverse relationships between TSC and cancer.
Inverse relationships were found for cancers of the liver/
intrahepatic bile duct, pancreas, non-melanoma of skin and
lymph/hematopoietic tissue among men and for gallbladder,
breast, melanoma of skin and lymph/hematopoietic tissue among
women. From these, only associations of TSC with colon cancer,
pancreas cancer, breast cancer, and skin cancer remained
significant in the lag-time analysis. Restricting analyses to
Cholesterol and Cancer
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measurements before 1994, the onset of statin medication,
revealed no major differences regarding the estimated associations.
In previous studies, the ‘‘preclinical cancer effect’’ hypothesis
[20] has received considerable attention as an explanation for
some of the observed inverse associations. That is, the inverse
relation between low TSC levels and cancer risk might be caused
by cancers in preclinical stages, as malignant neoplasm are known
to have protean physiological effect, which might include
metabolic depression of blood cholesterol [33]. Additional
evidence for reverse causation comes from Trompet et al’s
Mendelian randomization study [21] and a review on clinical
trials investigating the relationship of low cholesterol and disease
activity [34]. Furthermore, it has been suggested that inverse
cancer-cholesterol relationships could be explained by competing
risks, i.e that patients showing high TSC levels are more likely to
be censored due to cardiovascular mortality before they were
diagnosed with cancer [20].
Concerning site-specific cancers, reports on associations with
colon cancer are controversial. Positive as well as negative
associations have been observed [35,36]. Our results indicate
only a modest positive association among men and absence of
a relation among women.
Regarding liver cancer, our results are in line with previously
published results of the Me-Can study collaboration and other
studies, where mostly negative associations have been reported
that diminished with increasing lag-time periods [1,3,37,38].
There seems to be a general consensus that, when hepatic
inadequacy occurs because of liver cancer and chronic liver
disease, form, esterification and evacuation of cholesterol are
blocked, which causes changes in cholesterol levels [39].
For gallbladder/biliary tract cancer Andreotti et al [19]
reported a U-shaped association, with low levels as well as high
levels of cholesterol being linked with excess risks of biliary tract
cancers. This was not confirmed in our data; our results showed no
Table 1. Baseline characteristics of study participants in the Metabolic Syndrome and Cancer Project.
Oslo NCS CONOR 40-y VHM&PP VIP MPP
Inclusion period 1972–1973 1974–1983 1995–2003 1994–1999 1988–2002 1985–2005 1974–1992
Number (%) 16,760 (2.90) 51,024 (8.84) 109,868 (19.03) 128,887 (22.32) 159,280 (27.59) 78,818 (13.65) 32,693 (5.66)
Baseline age, years (mean (SD)) 44.1 (5.6) 40.3 (7.0) 47.5 (15.0) 41.5 (1.9) 42.7 (15.4) 45.6 (9.6) 45.6 (7.4)
Smoking status, (n(%))
Never smoker 3,303 (19.7) 18,022 (35.3) 48,859 (44.5) 24,042 (18.7) 105,328 (66.1) 45,756 (58.1) 12,170 (37.2)
Ex-smoker 3,975 (23.7) 9,185 (18.0) 28,255 (25.7) 80,959 (42.8) 13,960 (8.8) 16,292 (20.7) 5,882 (18.0)
Current smoker 9,482 (56.6) 23,817 (46.7) 32,754 (29.8) 23,886 (18.5) 39,992 (25.1) 15,291 (19.4) 14,589 (44.6)
Missing 0 0 0 0 0 1,479 (1.8) 52 (0.2)
BMI, kg/m2 (mean (SD)) 26.6 (2.9) 24.6 (3.5) 26.1 (4.1) 25.5 (3.8) 24.8 (4.2) 25.8 (4.0) 24.6 (3.6)
Cholesterol, mmol/l, (mean(SD)) 6.33 (1.19) 6.21 (1.26) 5.70 (1.18) 5.54 (1.01) 5.55 (1.19) 5.64 (1.19) 5.66 (1.08)
Quintiles, (mean (SD))
1 4.83 (0.47) 4.66 (0.42) 4.26 (0.41) 4.28 (0.40) 4.06 (0.41) 4.12 (0.49) 4.29 (0.40)
2 5.75 (0.18) 5.51 (0.20) 5.03 (0.20) 4.99 (0.23) 4.88 (0.18) 5.00 (0.20) 5.07 (0.18)
3 6.33 (0.16) 6.11 (0.20) 5.61 (0.19) 5.47 (0.25) 5.46 (0.18) 5.71 (0.20) 5.60 (0.17)
4 6.92 (0.19) 6.77 (0.26) 6.26 (0.23) 6.00 (0.30) 6.10 (0.22) 6.19 (0.25) 6.16 (0.21)
5 8.08 (0.83) 8.05 (0.98) 7.46 (0.74) 7.01 (0.73) 7.32 (0.82) 7.39 (0.79) 7.24 (0.76)
Hypercholesterolemia, (n (%))
.6.2 mmol/l
8,409 (50.2) 23,575 (46.2) 33,101 (30.1) 30,178 (23.4) 42,611 (26.8) 22,674 (28.8) 9,244 (28.3)
Fasting
,4 h 13,642 (81.4) 39,800 (78.0) 85,533 (77.9) 101,142 (78.5) 0 (0.0) 2,680 (3.4) 0 (0.0)
4 h–8 h 1,700 (10.1) 9,831 (19.27) 18,208 (16.57) 22,172 (17.20) 0 (0.0) 5,601 (7.1) 0 (0.0)
.8 h 1,418 (8.5) 1,393 (2.7) 6,127 (5.6) 5,573 (4.3) 159,280 (100.0) 70,537 (89.5) 32,693 (100.0)
Measurement method Non- enzymatic Non- enzymatic,
Enzymatic from
year 1980
Enzymatic Enzymatic Enzymatic Enzymatic Enzymatic
Follow-up, years (mean (SD)) 26.0 (8.0) 25.8 (6.2) 6.1 (2.4) 7.4 (1.6) 10.4 (4.5) 7.5 (4.2) 21.1 (6.3)
Categories, (n)
,1 69 183 902 364 458 6600 190
1–,5 447 1,087 42,663 2,083 27,978 23,381 1,035
5–,10 659 1,411 67,205 123,035 37,354 30,581 1,353
10– 15,654 48,546 0 3,769 93,948 24,856 30,305
Cancer cases, (n) 4,382 7,916 4,610 2,714 8,524 4,163 6,639
Abbreviations: BMI, body mass index; CONOR, Cohort of Norway; MPP, Malmo¨ Preventive Project; NCS, Norwegian Counties Study; Oslo, Oslo study I; SD, standard
deviation; VHM&PP, Vorarlberg Heath Monitoring and Prevention Programme; VIP, Va¨sterbotten Intervention Project; 40-y, Age 40-programme.
doi:10.1371/journal.pone.0054242.t001
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significant association in males and a clear inverse association in
females.
The amount of literature on pancreatic cancer and its
associations with cholesterol is limited. Two conducted studies
found no significant associations [40,41]. Our results differed
between males and females with inverse associations in males and
non-significant associations in females [42].
With regard to cancers of the lymph/hematopoietic tissue,
leukemic blood and bone narrow cells have been reported to show
an elevated low density lipoprotein-receptor activity that was
inversely associated with plasma cholesterol levels which might
explain hypocholesteraemia often seen in leukemic patients [33].
This interpretation is in line with our data, where associations of
blood cancer with TSC disappeared in the lag-time analysis.
Most investigations on breast cancer have not reported
significant associations with TSC [20,43,44]. However, our data
showed a clear negative association (see also [45]) that persisted
even when the first 10 years of follow-up were excluded, indicating
that reverse causation does not apply in this case. Further,
Fagherazzi et al [46] found a significantly decreased breast cancer
risk among women using cholesterol-lowering drugs. Unfortu-
nately, we do not have any data regarding statin prescription in
the Me-Can project to confirm this finding. Associations of TSC
with breast cancer were, however, similar in the pre-statin period
before 1994 and in the total observation period. Associations of
TSC with skin cancer where a debate is going on whether statin
use affects skin cancer outcomes [47,48], were also similar in the
two periods.
Recently several authors reported positive associations between
TSC levels and aggressive prostate cancer [11–13], even when
TSC was not associated with overall prostate cancer [11].
Unfortunately, we did not have information regarding prostate
cancer grading in our data, so we cannot contribute to this
discussion.
Strengths of our study include the large sample size of over
500,000 participants from seven European population-based
cohorts with virtually complete capture of cancer cases. We were
also able to correct risk estimates for regression dilution bias,
caused by random fluctuations in baseline measurements common
to long-term prospective studies, which might lead to underesti-
Table 2. RDR corrected hazard ratiosa of incident cancer by cholesterol in quintiles (compared to the lowest quintile) and per unit
increment in men.
Quintile
Site (ICD-7 code) 2 3 4 5
per 1
unit (mmol/l)
n cases HR 95% CI HR 95% CI HR HR 95% CI P trend HR 95% CI
Total cancer 23,142 0.95 0.89, 1.02 0.94 0.88, 1.00 0.94 0.88, 1.01 0.94 0.88, 1.00 0.11 0.98 0.97,1.00
Lip, oral cavity, pharynx
(140–149)
588 1.04 0.67, 1.61 0.93 0.60, 1.44 0.90 0.58, 1.40 1.38 0.91, 2.10 0.18 1.07 0.96, 1.19
Oesophagus (150) 248 0.95 0.48, 1.86 0.83 0.42, 1.63 0.79 0.40, 1.55 1.12 0.59, 2.12 0.79 0.99 0.84, 1.18
Stomach (151) 858 0.85 0.60, 1.22 0.78 0.55, 1.11 0.92 0.66, 1.30 0.71 0.50, 1.01 0.14 0.92 0.84, 1.01
Colon (153) 1,806 0.94 0.72, 1.22 1.19 0.93, 1.53 1.19 0.93, 1.52 1.18 0.92, 1.51 0.04 1.05 0.99, 1.12
Rectum, anus (154) 1,158 1.12 0.82, 1.53 0.97 0.71, 1.33 0.96 0.70, 1.31 1.09 0.81, 1.48 0.92 1.01 0.93, 1.09
Liver, intrahepatic bile ducts
(155.0)
194 0.33 0.17, 0.63 0.22 0.11, 0.43 0.26 0.13, 0.49 0.14 0.07, 0.29 ,0.01 0.58 0.46, 0.71
Gallbladder, biliary tract
(155.1–155.3)
98 1.16 0.38, 3.56 1.35 0.46, 3.98 1.03 0.34, 3.10 1.27 0.44, 3.69 0.80 1.10 0.84, 1.45
Pancreas (157) 520 0.63 0.41, 0.98 0.75 0.49, 1.14 0.63 0.41, 0.97 0.52 0.33, 0.81 0.01 0.86 0.76, 0.97
Larynx, trachea/bronchus/
lung (161,162)
2,922 1.01 0.83, 1.24 1.09 0.90, 1.33 0.97 0.80, 1.18 1.15 0.95, 1.40 0.22 1.03 0.98, 1.08
Prostate (177) 6,884 1.00 0.88, 1.14 1.05 0.93, 1.20 1.01 0.89 1.14 0.99 0.88, 1.13 0.86 0.99 0.96, 1.03
Testis (178) 278 0.80 0.46, 1.39 1.11 0.64, 1.93 1.34 0.76, 2.36 0.81 0.42, 1.56 0.77 0.97 0.81, 1.16
Kidney, renal cell (180.0–
180.9)
691 1.26 0.84, 1.88 0.99 0.66, 1.29 1.23 0.83, 1.83 1.06 0.71, 1.58 0.94 1.00 0.90, 1.11
Bladder (181) 1,573 1.27 0.97, 1.65 0.90 0.68, 1.18 1.04 0.80 1.35 1.11 0.85, 1.44 0.96 1.01 0.95, 1.09
Melanoma of skin (190) 1,074 0.87 0.64, 1.16 0.77 0.57, 1.04 0.76 0.56, 1.03 0.82 0.61, 1.11 0.15 0.93 0.85, 1.02
Non-melanoma of skin (191)782 0.77 0.54 1.10 0.70 0.49, 1.01 0.79 0.56, 1.13 0.67 0.46, 0.95 0.07 0.91 0.82, 1.01
Brain, nervous tissue (193) 427 0.91 0.56, 1.47 0.97 0.60, 1.55 0.82 0.50 1.33 0.86 0.53, 1.41 0.48 0.98 0.86, 1.12
Thyroid gland (194) 128 1.03 0.44, 2.40 0.77 0.32, 1.88 1.01 0.43, 2.40 0.64 0.25, 1.62 0.40 0.94 0.74, 1.21
Lymph/hematopoietic
tissue (200–209)
1,790 0.76 0.60, 0.97 0.75 0.59, 0.95 0.85 0.67, 1.07 0.68 0.54, 0.87 0.02 0.91 0.85, 0.97
Other cancer 1,123 0.94 0.69, 1.27 0.83 0.61, 1.13 0.85 0.63, 1.15 0.87 0.64, 1.18 0.31 0.96 0.89, 1.05
Abbreviations: CI, confidence interval; HR, hazard ratio; ICD-7, International Classification of Diseases, seventh revision.
aHRs estimated from Cox proportional hazard regression models with age as the time scale, stratified by cohort, fasting status, and birth year categories, adjusted for
baseline age, body mass index categories, and smoking status. HRs corrected for random error by regression dilution ratio (RDR); conversion into uncorrected
HR = exp(ln(HR)*RDR), where RDR = 0.644.
doi:10.1371/journal.pone.0054242.t002
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mation of the true risk. Furthermore, all analyses were adjusted for
potential confounders such as BMI and smoking status and
stratified by birth year, cohort and fasting time before measure-
ment.
On the other hand, our study is limited by the lack of
information of use of anti-hypercholesterol medication, such as
statins, behavioural aspects like dietary habits, physical activity and
alcohol consumption, as well as genetic variations that could have
influenced both cholesterol levels and cancer. Furthermore, we did
not have separate data on low and high density lipoprotein
cholesterol subfractions or detailed information on tumor staging.
In summary, TSC levels were negatively associated with risk of
cancer overall in females and risk of cancer at several sites in both
males and females. Also, a positive relation was found for colon
cancer in men. In the lag-time analysis some associations persisted,
suggesting that although competing risks and reverse causation
may explain the mainly inverse associations, some etiologic role for
this lipid fraction cannot be ruled out.
Supporting Information
Table S1 Uncorrected hazard ratios of incident cancer
by cholesterol in quintiles (compared to the lowest
quintile) and per unit increment in men.
(DOCX)
Table S2 Uncorrected hazard ratios of incident cancer
by cholesterol in quintiles (compared to the lowest
quintile) and per unit increment in women.
(DOCX)
Table S3 Uncorrected hazard ratios of incident cancer
by cholesterol in quintiles (compared to the lowest
quintile) and per unit increment in men, including
measurements before 1994.
(DOCX)
Table S4 Uncorrected hazard ratios of incident cancer
by cholesterol in quintiles (compared to the lowest
Table 3. RDR corrected hazard ratiosa of incident cancer by cholesterol in quintiles (compared to the lowest quintile) and per unit
increment in women.
Quintile
Site (ICD-7 code) n cases 2 3 4 5 per 1 unit (mmol/l)
HR 95% CI HR 95% CI HR 95% CI HR 95% CI P trend HR 95% CI
Total cancer 15,836 0.95 0.87, 1.03 0.93 0.85, 1.01 0.94 0.86, 1.02 0.86 0.79, 0.93 ,0.01 0.95 0.93, 0.97
Lip, oral cavity, pharynx
(140–149)
186 1.19 0.53, 2.68 0.75 0.32, 1.74 1.26 0.58, 2.75 1.13 0.51, 2.48 0.68 1.11 0.92, 1.34
Oesophagus (150) 47 1.17 0.17, 7.98 1.10 0.17, 7.21 3.29 0.61, 17.81 1.51 0.26, 8.83 0.35 1.02 0.70, 1.49
Stomach (151) 416 0.96 0.55, 1.68 0.62 0.35, 1.09 0.98 0.57, 1.64 0.84 0.50, 1.42 0.72 0.96 0.85, 1.09
Colon (153) 1,336 1.05 0.75, 1.48 1.19 0.86, 1.64 1.17 0.85, 1.61 1.23 0.90, 1.69 0.15 1.03 0.96, 1.10
Rectum, anus (154) 635 1.11 0.68, 1.81 1.43 0.90, 2.26 1.50 0.95, 2.35 1.48 0.94, 2.32 0.49 1.09 0.99, 1.21
Liver, intrahepatic bile ducts
(155.0)
71 2.87 0.69, 11.83 1.08 0.24, 4.86 1.09 0.25, 4.70 0.96 0.22, 4.07 0.24 0.73 0.53, 1.02
Gallbladder, biliary tract
(155.1–155.3)
104 0.94 0.35, 2.51 0.38 0.13, 1.09 0.47 0.18, 1.25 0.23 0.08, 0.62 ,0.01 0.66 0.50, 0.86
Pancreas (157) 324 0.86 0.45, 1.67 0.76 0.40, 1.45 0.97 0.53, 1.80 1.08 0.60, 1.97 0.44 1.06 0.92, 1.23
Larynx, trachea/bronchus/
lung (161,162)
947 0.83 0.56, 1.21 1.10 0.77, 1.57 1.04 0.73, 1.49 1.24 0.88, 1.76 0.05 1.03 0.95, 1.12
Breast (170) 5,228 0.93 0.81, 1.07 0.91 0.79, 1.04 0.84 0.73, 0.96 0.70 0.61, 0.81 ,0.01 0.90 0.86, 0.93
Cervix (171) 477 1.02 0.66, 1.59 0.97 0.62, 1.52 1.07 0.68, 1.67 1.05 0.66, 1.67 0.79 1.02 0.90, 1.16
Other parts of uterus
(172,174)
1,081 0.83 0.59, 1.16 0.87 0.63, 1.20 0.70 0.51, 0.97 0.74 0.54, 1.02 0.04 0.91 0.84, 0.99
Ovary (175.0) 733 1.06 0.71, 1.60 1.32 0.89, 1.95 1.42 0.96, 2.09 1.27 0.86, 1.89 0.12 1.06 0.96, 1.17
Kidney, renal cell (180.0–
180.9)
321 0.74 0.37, 1.48 1.12 0.60, 2.11 0.95 0.51, 1.79 1.13 0.61, 2.07 0.40 1.05 0.91, 1.21
Bladder (181) 325 0.74 0.39, 1.40 0.81 0.44, 1.49 0.70 0.38, 1.28 0.91 0.51, 1.62 1.00 0.95 0.82, 1.10
Melanoma of skin (190) 777 0.96 0.68, 1.34 0.68 0.48, 0.98 0.98 0.70, 1.38 0.61 0.42, 0.88 0.03 0.88 0.79, 0.98
Non-melanoma of skin (191)396 1.67 0.88, 3.16 1.12 0.59, 2.14 1.47 0.80, 2.72 1.52 0.83, 2.78 0.32 1.10 0.97, 1.25
Brain, nervous tissue (193) 258 0.74 0.40, 1.39 0.56 0.29, 1.08 0.92 0.50, 1.68 0.70 0.37, 1.31 0.54 0.95 0.80, 1.13
Thyroid gland (194) 259 1.17 0.64, 2.13 0.90 0.48, 1.67 0.93 0.50, 1.72 0.85 0.56, 1.30 0.31 0.88 0.73, 1.05
Lymph/hematopoietic
tissue (200–209)
1,094 0.77 0.56, 1.07 0.81 0.59, 1.11 0.77 0.57, 1.05 0.61 0.44, 0.83 0.01 0.85 0.78, 0.92
Other cancer 821 1.13 0.77, 1.65 1.10 0.75, 1.60 1.06 0.73, 1.54 0.94 0.64, 1.37 0.51 1.01 0.92, 1.11
Abbreviations: CI, confidence interval; HR, hazard ratio; ICD-7, International Classification of Diseases, seventh revision.
aHRs estimated from Cox proportional hazard regression models with age as the time scale, stratified by cohort, fasting status, and birth year categories, adjusted for
baseline age, body mass index categories, and smoking status. HRs corrected for random error by regression dilution ratio (RDR); conversion into uncorrected
HR = exp(ln(HR)*RDR), where RDR = 0.660.
doi:10.1371/journal.pone.0054242.t003
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quintile) and per unit increment in women, including
measurements before 1994.
(DOCX)
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